Market Overview:
The global antidiabetic drug market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The market growth is attributed to the increasing prevalence of diabetes, rising geriatric population, and technological advancements in the field of diabetes treatment. Based on type, the global antidiabetic drug market is segmented into alpha-glucosidase inhibitors, biguanides, sulphonylureas, glp-1 agonists, meglitinides Dpp-4 inhibitors Sglt2 inhibitors and thiazolodinediones. Based on application type I diabetes and type II diabetes are classified.
Product Definition:
Antidiabetic drugs are medications used to treat diabetes mellitus. They lower blood sugar levels by increasing the amount of insulin produced by the pancreas, decreasing the amount of sugar that is absorbed from food, or both.
Alpha-Glucosidase Inhibitors:
Alpha-glucosidase inhibitors are a class of antidiabetic drugs that prevent the release of glucose from blood cells by blocking the action of alpha-glucosidase, an enzyme responsible for its production. Alpha-glucosidase inhibitors lower postprandial blood sugar levels and improve insulin sensitivity in patients with type 2 diabetes mellitus.
Biguanides, Sulphonylureas:
Biguanides, sulphonylureas and its derivatives are used in the treatment of type II diabetes. They act by increasing the sensitivity of insulin to glucose levels in the body. The drug decreases or eliminates symptoms such as frequent urination, excessive thirst, dry mouth and fatigue along with lowering blood sugar levels. It is also used to treat patients who have been recently diagnosed with type I diabetes (insulin-dependent diabetes) or those who are at risk of developing type I diabetes.
Application Insights:
Application segments analyzed in the study include type I and other diabetes and type II diabetes. In 2017, application for antidiabetic drugs for treatment of type I accounted for the largest share owing to high prevalence of this form of diabetes. The U.S., Germany, France, Brazil, UK among others are estimated to have significant penetration in terms of revenue as well as volume due to high incidence rate and prevalence in these regions.
Type II is also known as adult-onset or non- insulin-dependent diabetes which accounts for approximately 90% - 95%of the total diabetic population globally. This form can be diagnosed at any age but its symptoms usually emerge after 40 years of age leading to diagnosis around that time span only (late diagnosis).
Regional Analysis:
North America dominated the global antidiabetic drug market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of diabetes are some factors responsible for its large share. In addition, the region is expected to witness a significant growth rate owing to rising healthcare expenditure and improved access to medicines due to various programs implemented by governments & non-government organizations. For instance, in May 2018 ‘Diabetes Month’ was celebrated with an aim to increase awareness about diabetes prevention among youth population in U.S., which also included educational events such as health fairs and demonstrations at local malls that provided free samples and information about new products (such as metformin hydrochloride) along with other benefits (such as weight loss).
Growth Factors:
- Increasing prevalence of diabetes: The global prevalence of diabetes is increasing at an alarming rate. This is mainly due to the changing lifestyle and dietary habits of people across the world. As a result, there is a growing demand for antidiabetic drugs to control blood sugar levels in diabetic patients.
- Rising awareness about diabetes and its complications: There is a growing awareness among people about the dangers of uncontrolled blood sugar levels in diabetics. This has led to an increase in the demand for antidiabetic drugs, as more and more people are seeking treatment for their condition.
- Technological advancements in drug development: The pharmaceutical industry is making significant advances in drug development technologies, which are helping to accelerate the discovery and development of new antidiabetic drugs. This is resulting in increased competition among manufacturers, which is benefiting consumers by driving down prices and improving product quality.
Scope Of The Report
Report Attributes
Report Details
Report Title
Antidiabetic Drug Market Research Report
By Type
Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones
By Application
Type I Diabetes, Type II Diabetes
By Companies
Sanofi-Aventis, Eli Lilly, Oramed, Takeda, Boehringer Ingelheim, Novo Nordisk, Halozyme Therapeutics, Bristol-Myers Squibb, Pfizer, Tonghua Dongbao, Sanofi-Aventis, Wockhardt
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
210
Number of Tables & Figures
147
Customization Available
Yes, the report can be customized as per your need.
Global Antidiabetic Drug Market Report Segments:
The global Antidiabetic Drug market is segmented on the basis of:
Types
Alpha-Glucosidase Inhibitors, Biguanides, Sulphonylureas, Glp-1 Agonist, Meglitinides, Dpp-4 Inhibitors, Sglt–2, Thiazolodinediones
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Type I Diabetes, Type II Diabetes
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sanofi-Aventis
- Eli Lilly
- Oramed
- Takeda
- Boehringer Ingelheim
- Novo Nordisk
- Halozyme Therapeutics
- Bristol-Myers Squibb
- Pfizer
- Tonghua Dongbao
- Sanofi-Aventis
- Wockhardt
Highlights of The Antidiabetic Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Alpha-Glucosidase Inhibitors
- Biguanides, Sulphonylureas
- Glp-1 Agonist
- Meglitinides
- Dpp-4 Inhibitors
- Sglt–2
- Thiazolodinediones
- By Application:
- Type I Diabetes
- Type II Diabetes
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Antidiabetic Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Antidiabetic drug is a type of medication that helps to control blood sugar levels in people with diabetes. Antidiabetic drugs can be prescribed alone or in combination with other medications.
Some of the major players in the antidiabetic drug market are Sanofi-Aventis, Eli Lilly, Oramed, Takeda, Boehringer Ingelheim, Novo Nordisk, Halozyme Therapeutics, Bristol-Myers Squibb, Pfizer, Tonghua Dongbao, Sanofi-Aventis, Wockhardt.
The antidiabetic drug market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Antidiabetic Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Antidiabetic Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Antidiabetic Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Antidiabetic Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Antidiabetic Drug Market Size & Forecast, 2018-2028
4.5.1 Antidiabetic Drug Market Size and Y-o-Y Growth
4.5.2 Antidiabetic Drug Market Absolute $ Opportunity
Chapter 5 Global Antidiabetic Drug Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Antidiabetic Drug Market Size Forecast by Type
5.2.1 Alpha-Glucosidase Inhibitors
5.2.2 Biguanides
5.2.3 Sulphonylureas
5.2.4 Glp-1 Agonist
5.2.5 Meglitinides
5.2.6 Dpp-4 Inhibitors
5.2.7 Sglt–2
5.2.8 Thiazolodinediones
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Antidiabetic Drug Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Antidiabetic Drug Market Size Forecast by Applications
6.2.1 Type I Diabetes
6.2.2 Type II Diabetes
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Antidiabetic Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Antidiabetic Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Antidiabetic Drug Analysis and Forecast
9.1 Introduction
9.2 North America Antidiabetic Drug Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Antidiabetic Drug Market Size Forecast by Type
9.6.1 Alpha-Glucosidase Inhibitors
9.6.2 Biguanides
9.6.3 Sulphonylureas
9.6.4 Glp-1 Agonist
9.6.5 Meglitinides
9.6.6 Dpp-4 Inhibitors
9.6.7 Sglt–2
9.6.8 Thiazolodinediones
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Antidiabetic Drug Market Size Forecast by Applications
9.10.1 Type I Diabetes
9.10.2 Type II Diabetes
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Antidiabetic Drug Analysis and Forecast
10.1 Introduction
10.2 Europe Antidiabetic Drug Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Antidiabetic Drug Market Size Forecast by Type
10.6.1 Alpha-Glucosidase Inhibitors
10.6.2 Biguanides
10.6.3 Sulphonylureas
10.6.4 Glp-1 Agonist
10.6.5 Meglitinides
10.6.6 Dpp-4 Inhibitors
10.6.7 Sglt–2
10.6.8 Thiazolodinediones
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Antidiabetic Drug Market Size Forecast by Applications
10.10.1 Type I Diabetes
10.10.2 Type II Diabetes
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Antidiabetic Drug Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Antidiabetic Drug Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Antidiabetic Drug Market Size Forecast by Type
11.6.1 Alpha-Glucosidase Inhibitors
11.6.2 Biguanides
11.6.3 Sulphonylureas
11.6.4 Glp-1 Agonist
11.6.5 Meglitinides
11.6.6 Dpp-4 Inhibitors
11.6.7 Sglt–2
11.6.8 Thiazolodinediones
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Antidiabetic Drug Market Size Forecast by Applications
11.10.1 Type I Diabetes
11.10.2 Type II Diabetes
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Antidiabetic Drug Analysis and Forecast
12.1 Introduction
12.2 Latin America Antidiabetic Drug Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Antidiabetic Drug Market Size Forecast by Type
12.6.1 Alpha-Glucosidase Inhibitors
12.6.2 Biguanides
12.6.3 Sulphonylureas
12.6.4 Glp-1 Agonist
12.6.5 Meglitinides
12.6.6 Dpp-4 Inhibitors
12.6.7 Sglt–2
12.6.8 Thiazolodinediones
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Antidiabetic Drug Market Size Forecast by Applications
12.10.1 Type I Diabetes
12.10.2 Type II Diabetes
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Antidiabetic Drug Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Type
13.6.1 Alpha-Glucosidase Inhibitors
13.6.2 Biguanides
13.6.3 Sulphonylureas
13.6.4 Glp-1 Agonist
13.6.5 Meglitinides
13.6.6 Dpp-4 Inhibitors
13.6.7 Sglt–2
13.6.8 Thiazolodinediones
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Antidiabetic Drug Market Size Forecast by Applications
13.10.1 Type I Diabetes
13.10.2 Type II Diabetes
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Antidiabetic Drug Market: Competitive Dashboard
14.2 Global Antidiabetic Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sanofi-Aventis
14.3.2 Eli Lilly
14.3.3 Oramed
14.3.4 Takeda
14.3.5 Boehringer Ingelheim
14.3.6 Novo Nordisk
14.3.7 Halozyme Therapeutics
14.3.8 Bristol-Myers Squibb
14.3.9 Pfizer
14.3.10 Tonghua Dongbao
14.3.11 Sanofi-Aventis
14.3.12 Wockhardt
